Executive Summary: Lateral Flow Technology and the Future of Point of Care Diagnostics

Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market.

The report from which this Executive Summary is compiled is Lateral Flow Technology and the Future of Point of Care Diagnostics, and the full study abstract is as follows:

Lateral flow tests, also known as immunochromatographic strip (ICS) tests, offer dramatic benefits in the diagnostic process that point towards a robust market. LF tests reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and manufacturing.

Rapid point of care testing devices will play an increasingly important role in the decentralization of medicine, where testing is moving away from hospitals and to pharmacies and even shopping malls, a trend that will fuel exponential growth. Despite these certain trends, competition is heavy and there are issues and trends affecting this market that new entrants need to be aware of.

Kalorama’s Lateral Flow Technology and the Future of Point of Care Diagnostics, is a perspective on the past and future of rapid clinical tests, is your guide to this increasingly crowded LF testing market place. Kalorama’s report cuts through the hype about the lateral flow point of care marketplace and provides a realistic assessment of this growing field. Every critical aspect of the LF market is addressed, including the following key topics:

• The current sales figures and realistic projections for 2010.
• The core factors driving LF testing revenues up.
• The growing number of need-to-know companies in Lateral Flow Test devices.
• The trends to watch that could increase sales predictions.
• Expected gains to be made by LF POC devices over lab-based immunoassays across categories.
• Obstacles that could trap new entrants.
• An interview with the original developer of LF testing technology with his take on where this market is headed.